Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 531

1.

Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease.

Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, Scharl M, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.

United European Gastroenterol J. 2019 Jul;7(6):767-781. doi: 10.1177/2050640619841249. Epub 2019 Mar 27.

2.

Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.

Egli-Spichtig D, Imenez Silva PH, Glaudemans B, Gehring N, Bettoni C, Zhang MYH, Pastor-Arroyo EM, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler GM, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger RH, Frew I, Wagner CA.

Kidney Int. 2019 May 14. pii: S0085-2538(19)30465-X. doi: 10.1016/j.kint.2019.04.009. [Epub ahead of print]

PMID:
31301888
3.

Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.

D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, Danese S; IOIBD Fibrosis Working Group.

Gastroenterology. 2019 Jun 26. pii: S0016-5085(19)41035-4. doi: 10.1053/j.gastro.2019.05.072. [Epub ahead of print]

PMID:
31254502
4.

The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis.

Raselli T, Wyss A, Gonzalez Alvarado MN, Weder B, Mamie C, Spalinger MR, Van Haaften WT, Dijkstra G, Sailer AW, Imenez Silva PH, Wagner CA, Tosevski V, Leibl S, Scharl M, Rogler G, Hausmann M, Misselwitz B.

J Crohns Colitis. 2019 Apr 11. pii: jjz039. doi: 10.1093/ecco-jcc/jjz039. [Epub ahead of print]

PMID:
31220227
5.

Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis.

Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B.

J Lipid Res. 2019 Jul;60(7):1270-1283. doi: 10.1194/jlr.M093229. Epub 2019 May 21.

6.

Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner.

Spalinger MR, Schmidt TS, Schwarzfischer M, Hering L, Atrott K, Lang S, Gottier C, Geirnaert A, Lacroix C, Dai X, Rawlings DJ, Chan AC, von Mering C, Rogler G, Scharl M.

J Clin Invest. 2019 May 20;129(6):2527-2541. doi: 10.1172/JCI123263. eCollection 2019 May 20.

7.

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.

Hiller A, Biedermann L, Fournier N, Butter M, Vavricka SR, Ciurea A, Rogler G, Scharl M; Swiss IBD Cohort Study Group.

PLoS One. 2019 Apr 30;14(4):e0211554. doi: 10.1371/journal.pone.0211554. eCollection 2019.

8.

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study.

Bon L, Scharl S, Vavricka S, Rogler G, Fournier N, Pittet V, Scharl M, Greuter T, Schreiner P, Frei P, Misselwitz B, Biedermann L, Zeitz J; Swiss IBD Cohort Study Group.

PLoS One. 2019 Apr 25;14(4):e0215738. doi: 10.1371/journal.pone.0215738. eCollection 2019.

9.

Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease.

Schoepfer A, Santos J, Fournier N, Schibli S, Spalinger J, Vavricka S, Safroneeva E, Aslan N, Rogler G, Braegger C, Nydegger A; Swiss IBD Cohort Study group.

J Crohns Colitis. 2019 Apr 19. pii: jjz065. doi: 10.1093/ecco-jcc/jjz065. [Epub ahead of print]

PMID:
31002741
10.

The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.

Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, Pittet VEH; Swiss IBD Cohort Study Group .

J Crohns Colitis. 2019 May 27;13(6):744-754. doi: 10.1093/ecco-jcc/jjz003.

PMID:
30916775
11.

Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn's Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study.

Frei R, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2019 Mar 7. pii: jjz057. doi: 10.1093/ecco-jcc/jjz057. [Epub ahead of print]

PMID:
30854548
12.

Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease.

Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; Swiss IBD Cohort Investigators, Wiest R, Stelling J, Macpherson AJ.

Nat Med. 2019 Apr;25(4):701. doi: 10.1038/s41591-019-0411-9.

PMID:
30846883
13.

Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.

Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R.

Inflamm Bowel Dis. 2019 Jul 17;25(8):1357-1366. doi: 10.1093/ibd/izz012.

PMID:
30776076
14.

The long and winding road: from genetic risk factors to the understanding of disease-pathogenesis in Crohn's disease.

Rogler G, Hausmann M.

Genes Immun. 2019 Feb 18. doi: 10.1038/s41435-019-0060-5. [Epub ahead of print] No abstract available.

PMID:
30773533
15.

The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.

Wyss A, Raselli T, Perkins N, Ruiz F, Schmelczer G, Klinke G, Moncsek A, Roth R, Spalinger MR, Hering L, Atrott K, Lang S, Frey-Wagner I, Mertens JC, Scharl M, Sailer AW, Pabst O, Hersberger M, Pot C, Rogler G, Misselwitz B.

Mucosal Immunol. 2019 May;12(3):733-745. doi: 10.1038/s41385-019-0140-x. Epub 2019 Feb 11.

16.

Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor-κB in the Intestinal Epithelium.

Simmen S, Cosin-Roger J, Melhem H, Maliachovas N, Maane M, Baebler K, Weder B, Maeyashiki C, Spanaus K, Scharl M, de Vallière C, Zeitz J, Vavricka SR, Hausmann M, Rogler G, Ruiz PA.

Cell Mol Gastroenterol Hepatol. 2019;7(2):339-355. doi: 10.1016/j.jcmgh.2018.10.006. Epub 2018 Oct 17.

17.

Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS).

Pittet V, Michetti P, Mueller C, Braegger CP, von Känel R, Schoepfer A, Macpherson AJ, Rogler G; Swiss IBD Cohort Study Group, Anderegg C, Bauerfeind P, Beglinger C, Begré S, Belli D, Bengoa J, Biedermann L, Bigler B, Binek J, Blattmann M, Boehm S, Borovicka J, Braegger P, Brunner N, Bühr P, Burnand B, Burri E, Buyse S, Cremer M, Criblez DH, de Saussure P, Degen L, Delarive J, Doerig C, Dora B, Dorta G, Egger M, Ehmann T, El-Wafa A, Engelmann M, Ezri J, Felley C, Fliegner M, Fournier N, Fraga M, Frei P, Fried M, Froehlich F, Funk C, Furlano RI, Gallot-Lavallée S, Geyer M, Girardin M, Golay D, Grandinetti T, Gysi B, Haack H, Haarer J, Helbling B, Hengstler P, Herzog D, Hess C, Heyland K, Hinterleitner T, Hiroz P, Hirschi C, Hruz P, Iwata R, Jost R, Juillerat P, Keller C, Knellwolf C, Knoblauch C, Köhler H, Koller R, Krieger-Grübel C, Kullak-Ublick G, Künzler P, Landolt M, Lange R, Lehmann FS, Macpherson A, Maerten P, Maillard H, Manser C, Manz M, Marbet U, Marx G, Matter C, Meier R, Mendanova M, Michetti P, Misselwitz B, Morell B, Mosler P, Mottet C, Müller C, Müller P, Müllhaupt B, Münger-Beyeler C, Musso L, Nagy A, Neagu M, Nichita C, Niess J, Nydegger A, Obialo N, Oneta C, Oropesa C, Peter U, Peternac D, Petit LM, Piccoli-Gfeller F, Pilz JB, Pittet V, Raschle N, Rentsch R, Restellini RS, Richterich JP, Rihs S, Ritz MA, Roduit J, Rogler D, Rogler G, Rossel JB, Rueger V, Saner G, Sauter B, Sawatzki M, Schäppi M, Scharl M, Scharl S, Schelling M, Schibli S, Schlauri H, Uebelhart SS, Schnegg JF, Schoepfer A, Seibold F, Seirafi M, Semadeni GM, Semela D, Senning A, Sidler M, Sokollik C, Spalinger J, Spangenberger H, Stadler P, Steuerwald M, Straumann A, Straumann-Funk B, Sulz M, Suter A, Thorens J, Tiedemann S, Tutuian R, Vavricka S, Viani F, Vögtlin J, Von Känel R, Vonlaufen A, Vouillamoz D, Vulliamy R, Wermuth J, Werner H, Wiesel P, Wiest R, Wylie T, Zeitz J, Zimmermann D.

Int J Epidemiol. 2019 Jan 27. doi: 10.1093/ije/dyy298. [Epub ahead of print] No abstract available.

PMID:
30689927
18.

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.

Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, Scharl M; Swiss IBD Cohort Study Group.

PLoS One. 2019 Jan 25;14(1):e0210436. doi: 10.1371/journal.pone.0210436. eCollection 2019.

19.

Microbial network disturbances in relapsing refractory Crohn's disease.

Yilmaz B, Juillerat P, Øyås O, Ramon C, Bravo FD, Franc Y, Fournier N, Michetti P, Mueller C, Geuking M, Pittet VEH, Maillard MH, Rogler G; Swiss IBD Cohort Investigators, Wiest R, Stelling J, Macpherson AJ.

Nat Med. 2019 Feb;25(2):323-336. doi: 10.1038/s41591-018-0308-z. Epub 2019 Jan 21. Erratum in: Nat Med. 2019 Apr;25(4):701.

PMID:
30664783
20.

β6 -integrin serves as a novel serum tumor marker for colorectal carcinoma.

Bengs S, Becker E, Busenhart P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, Scharl M.

Int J Cancer. 2019 Aug 1;145(3):678-685. doi: 10.1002/ijc.32137. Epub 2019 Jan 29.

PMID:
30653264
21.

The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation.

Tcymbarevich IV, Eloranta JJ, Rossel JB, Obialo N, Spalinger M, Cosin-Roger J, Lang S, Kullak-Ublick GA, Wagner CA, Scharl M, Seuwen K, Ruiz PA, Rogler G, de Vallière C, Misselwitz B; Swiss IBD Cohort Study Group.

BMC Gastroenterol. 2019 Jan 7;19(1):2. doi: 10.1186/s12876-018-0922-8.

22.

Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis.

Spalinger MR, Atrott K, Baebler K, Schwarzfischer M, Melhem H, Peres DR, Lalazar G, Rogler G, Scharl M, Frey-Wagner I.

J Crohns Colitis. 2019 May 27;13(6):785-797. doi: 10.1093/ecco-jcc/jjy213.

PMID:
30590526
23.

Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas.

Bruckner RS, Nissim-Eliraz E, Marsiano N, Nir E, Shemesh H, Leutenegger M, Gottier C, Lang S, Spalinger MR, Leibl S, Rogler G, Yagel S, Scharl M, Shpigel NY.

J Crohns Colitis. 2019 May 27;13(6):798-806. doi: 10.1093/ecco-jcc/jjy226.

PMID:
30590414
24.

Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease.

Tcymbarevich I, Richards SM, Russo G, Kühn-Georgijevic J, Cosin-Roger J, Baebler K, Lang S, Bengs S, Atrott K, Bettoni C, Gruber S, Frey-Wagner I, Scharl M, Misselwitz B, Wagner CA, Seuwen K, Rogler G, Ruiz PA, Spalinger M, de Vallière C.

J Crohns Colitis. 2019 Feb 1;13(2):245-258. doi: 10.1093/ecco-jcc/jjy152.

PMID:
30535144
25.

Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data.

Bettenworth D, Mücke MM, Lopez R, Singh A, Zhu W, Guo F, Matsui T, James TW, Herfarth H, Goetz M, Mao R, Kurada S, Hampe J, Matthes K, Karstensen JG, Valli PV, Duijvestein M, D'Haens G, Jairath V, Qiu TB, Ding NS, Rogler G, Rieder F.

Clin Gastroenterol Hepatol. 2018 Nov 29. pii: S1542-3565(18)31325-9. doi: 10.1016/j.cgh.2018.11.048. [Epub ahead of print]

26.

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.

Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W.

Gastroenterology. 2019 Mar;156(4):946-957.e18. doi: 10.1053/j.gastro.2018.11.035. Epub 2018 Nov 23.

27.

Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals.

Pittet V, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P.

Clin Gastroenterol Hepatol. 2018 Nov 22. pii: S1542-3565(18)31272-2. doi: 10.1016/j.cgh.2018.11.029. [Epub ahead of print]

PMID:
30471455
28.

Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study.

Wotzka SY, Kreuzer M, Maier L, Zünd M, Schlumberger M, Nguyen B, Fox M, Pohl D, Heinrich H, Rogler G, Biedermann L, Scharl M, Sunagawa S, Hardt WD, Misselwitz B.

PLoS One. 2018 Oct 25;13(10):e0206214. doi: 10.1371/journal.pone.0206214. eCollection 2018.

29.

Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.

Scharl S, Barthel C, Rossel JB, Biedermann L, Misselwitz B, Schoepfer AM, Straumann A, Vavricka SR, Rogler G, Scharl M, Greuter T.

Am J Gastroenterol. 2019 Jan;114(1):116-126. doi: 10.1038/s41395-018-0360-9.

PMID:
30333538
30.

Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care.

Chmiel C, Vavricka SR, Hasler S, Rogler G, Zahnd N, Schiesser S, Tandjung R, Scherz N, Rosemann T, Senn O.

J Eval Clin Pract. 2019 Feb;25(1):155-162. doi: 10.1111/jep.13046. Epub 2018 Oct 15.

PMID:
30324695
31.

Severity of local inflammation does not impact development of fibrosis in mouse models of intestinal fibrosis.

Hünerwadel A, Fagagnini S, Rogler G, Lutz C, Jaeger SU, Mamie C, Weder B, Ruiz PA, Hausmann M.

Sci Rep. 2018 Oct 12;8(1):15182. doi: 10.1038/s41598-018-33452-5.

32.

Succinate receptor mediates intestinal inflammation and fibrosis.

Macias-Ceja DC, Ortiz-Masiá D, Salvador P, Gisbert-Ferrándiz L, Hernández C, Hausmann M, Rogler G, Esplugues JV, Hinojosa J, Alós R, Navarro F, Cosin-Roger J, Calatayud S, Barrachina MD.

Mucosal Immunol. 2019 Jan;12(1):178-187. doi: 10.1038/s41385-018-0087-3. Epub 2018 Oct 2.

PMID:
30279517
33.

The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding.

Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M.

United European Gastroenterol J. 2018 Aug;6(7):1007-1014. doi: 10.1177/2050640618774416. Epub 2018 May 28.

34.

Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells.

Leutenegger M, Bruckner R, Spalinger MR, Lang S, Rogler G, Scharl M.

Inflamm Intest Dis. 2018 Jul;2(4):211-218. doi: 10.1159/000490052. Epub 2018 Jul 10.

35.

The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives.

Arnott I, Rogler G, Halfvarson J.

Inflamm Intest Dis. 2018 Jul;2(4):189-199. doi: 10.1159/000490053. Epub 2018 Jun 26. Review.

36.

Growth of Epithelial Organoids in a Defined Hydrogel.

Broguiere N, Isenmann L, Hirt C, Ringel T, Placzek S, Cavalli E, Ringnalda F, Villiger L, Züllig R, Lehmann R, Rogler G, Heim MH, Schüler J, Zenobi-Wong M, Schwank G.

Adv Mater. 2018 Oct;30(43):e1801621. doi: 10.1002/adma.201801621. Epub 2018 Sep 10.

37.

Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of Inflammation.

Svrcek M, Borralho Nunes P, Villanacci V, Beaugerie L, Rogler G, De Hertogh G, Tripathi M, Feakins R; H-ECCO group.

J Crohns Colitis. 2018 Nov 28;12(12):1486-1498. doi: 10.1093/ecco-jcc/jjy132. Review.

PMID:
30202940
38.

Correction: Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease.

Kamm F, Strauch U, Degenhardt F, Lopez R, Kunst C, Rogler G, Franke A, Klebl F, Rieder F.

PLoS One. 2018 Sep 4;13(9):e0203709. doi: 10.1371/journal.pone.0203709. eCollection 2018.

39.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

40.

Inflammatory Bowel Disease in Travelers.

Rogler G.

Gastroenterol Hepatol (N Y). 2018 Jun;14(6):377-379. No abstract available.

41.

Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course.

Greuter T, Piller A, Fournier N, Safroneeva E, Straumann A, Biedermann L, Godat S, Nydegger A, Scharl M, Rogler G, Vavricka SR, Schoepfer AM; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2018 Nov 28;12(12):1399-1409. doi: 10.1093/ecco-jcc/jjy121.

PMID:
30165603
42.

Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis.

Hutter S, van Haaften WT, Hünerwadel A, Baebler K, Herfarth N, Raselli T, Mamie C, Misselwitz B, Rogler G, Weder B, Dijkstra G, Meier CF, de Vallière C, Weber A, Imenez Silva PH, Wagner CA, Frey-Wagner I, Ruiz PA, Hausmann M.

J Crohns Colitis. 2018 Nov 15;12(11):1348-1358. doi: 10.1093/ecco-jcc/jjy118.

43.

Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis.

Yassin M, Sadowska Z, Tritsaris K, Kissow H, Hansen CHF, Forman JL, Rogler G, Troelsen JT, Pedersen AE, Olsen J.

J Crohns Colitis. 2018 Nov 28;12(12):1459-1474. doi: 10.1093/ecco-jcc/jjy112.

PMID:
30137286
44.

Mechanism of action of vedolizumab: do we really understand it?

Rogler G.

Gut. 2019 Jan;68(1):4-5. doi: 10.1136/gutjnl-2018-316777. Epub 2018 Aug 4. No abstract available.

PMID:
30077996
45.

The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.

Russi L, Scharl M, Rogler G, Biedermann L.

Inflamm Intest Dis. 2017 Nov;2(2):131-138. doi: 10.1159/000481400. Epub 2017 Oct 19.

46.

The Impact of Cold Spells on the Incidence of Infectious Gastroenteritis and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study.

Manser CN, Kraus A, Frei T, Rogler G, Held L.

Inflamm Intest Dis. 2017 Nov;2(2):124-130. doi: 10.1159/000477807. Epub 2017 Jul 15.

47.

The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.

Yilmaz B, Spalinger MR, Biedermann L, Franc Y, Fournier N, Rossel JB, Juillerat P, Rogler G, Macpherson AJ, Scharl M.

PLoS One. 2018 Jul 2;13(7):e0199664. doi: 10.1371/journal.pone.0199664. eCollection 2018.

48.

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.

Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2018 Aug;48(3):347-357. doi: 10.1111/apt.14853. Epub 2018 Jun 19.

49.

Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Between Ulcerative Colitis and Crohn's Disease and Determines Their Capacity to Suppress Th1 Cells.

Beswick EJ, Grim C, Singh A, Aguirre JE, Tafoya M, Qiu S, Rogler G, McKee R, Samedi V, Ma TY, Reyes VE, Powell DW, Pinchuk IV.

Front Immunol. 2018 May 30;9:1125. doi: 10.3389/fimmu.2018.01125. eCollection 2018.

50.

BCL2 Regulates Differentiation of Intestinal Fibroblasts.

Weder B, Mamie C, Rogler G, Clarke S, McRae B, Ruiz PA, Hausmann M.

Inflamm Bowel Dis. 2018 May 22. doi: 10.1093/ibd/izy147. [Epub ahead of print]

PMID:
29796658

Supplemental Content

Loading ...
Support Center